First Time Loading...

Abbvie Inc
NYSE:ABBV

Watchlist Manager
Abbvie Inc Logo
Abbvie Inc
NYSE:ABBV
Watchlist
Price: 180.35 USD 0.65% Market Closed
Updated: Mar 28, 2024

Abbvie Inc
Cash from Financing Activities

Last Value
3-Years CAGR
5-Years CAGR
Quarterly
Annual
TTM
|

Abbvie Inc
Cash from Financing Activities Peer Comparison

Comparables:
GILD
AMGN
VRTX
REGN
SGEN

Competitive Cash from Financing Activities Analysis
Latest Figures & CAGR of Competitors

Company Cash from Financing Activities CAGR 3Y CAGR 5Y CAGR 10Y
Abbvie Inc
NYSE:ABBV
Cash from Financing Activities
$-17.2B
CAGR 3-Years
-14%
CAGR 5-Years
-4%
CAGR 10-Years
-17%
Gilead Sciences Inc
NASDAQ:GILD
Cash from Financing Activities
$-5.1B
CAGR 3-Years
N/A
CAGR 5-Years
16%
CAGR 10-Years
-7%
Amgen Inc
NASDAQ:AMGN
Cash from Financing Activities
$21B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
23%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Cash from Financing Activities
$-562.2m
CAGR 3-Years
-4%
CAGR 5-Years
-51%
CAGR 10-Years
N/A
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Cash from Financing Activities
$-1.8B
CAGR 3-Years
3%
CAGR 5-Years
-88%
CAGR 10-Years
N/A
Seagen Inc
NASDAQ:SGEN
Cash from Financing Activities
$124.7m
CAGR 3-Years
7%
CAGR 5-Years
-30%
CAGR 10-Years
12%

See Also

What is Abbvie Inc's Cash from Financing Activities?
Cash from Financing Activities
-17.2B USD

Based on the financial report for Dec 31, 2023, Abbvie Inc's Cash from Financing Activities amounts to -17.2B USD.

What is Abbvie Inc's Cash from Financing Activities growth rate?
Cash from Financing Activities CAGR 10Y
-17%

Over the last year, the Cash from Financing Activities growth was 31%. The average annual Cash from Financing Activities growth rates for Abbvie Inc have been -14% over the past three years , -4% over the past five years , and -17% over the past ten years .